# Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

> **NCT02639910** · PHASE2 · COMPLETED · sponsor: **MorphoSys AG** · enrollment: 24 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Tafasitamab
- **DRUG:** Idelalisib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02639910
- **Lead sponsor:** MorphoSys AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-11
- **Final completion:** 2021-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639910, "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02639910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*